Last updated: February 23, 2026
What is NDC 69238-1574?
NDC 69238-1574 is a prescription drug product identified in the National Drug Code (NDC) database. Based on available data, it corresponds to Sildenafil Citrate Tablets, 50 mg manufactured by a generic pharmaceutical company. Sildenafil is primarily used for erectile dysfunction and, in some cases, pulmonary arterial hypertension.
Market Size and Demand
Key facts:
- Indications: Erectile dysfunction (ED), pulmonary hypertension.
- Market estimates: The U.S. ED treatment market was valued at approximately USD 1.3 billion in 2022, with Sildenafil accounting for a substantial share.
- Prescription volume: Approximately 150 million prescriptions annually in the U.S., with Sildenafil representing 60-70% of ED prescriptions.
Competitive landscape:
- Leading brands: Viagra (Pfizer), Cialis (Eli Lilly), and Levitra (Bayer).
- Generic penetration: Since patent expiry in 2017, generics have captured around 80% of market share.
- Generic providers: Multiple firms supply Sildenafil generics, leading to intense price competition.
Pricing Overview
Historical pricing:
- Brand-name Viagra: Retail price approximately USD 60-70 per tablet.
- Generics (including NDC 69238-1574): Retail prices typically range USD 0.50–USD 2.00 per tablet depending on quantity discounts and pharmacy.
Wholesale Price:
- Average wholesale price (AWP): USD 0.50–USD 1.50 per tablet for generics.
- Average manufacturer net price: Estimated at USD 0.30–USD 1.00 per tablet.
Reimbursement and Insurance:
- Medicare/Medicaid: Reimbursements generally align with wholesale prices minus patient co-payments.
- Private insurers: Negotiated discounts often reduce costs further.
Price Projection Factors
Market Dynamics:
- Patent expiry: Since 2017, prices stabilized at lower levels due to generics.
- Supply chain: Increased manufacturing capacity from multiple firms sustains low prices.
- Regulatory decisions: No recent patent litigations or exclusivity grants expected to influence prices.
Potential price trends:
- In the next 3–5 years, price decline for this generic is unlikely, given widespread generic availability.
- Price stabilization: Expect prices to remain within USD 0.50–USD 2.00 per tablet.
- Premium formulations (e.g., extended-release, higher doses) may command higher prices but are distinct products.
Impact of New Approvals:
- No recent FDA approvals or formulations targeting specific markets forecasted to significantly alter current pricing.
- The entry of biosimilars or alternative delivery methods could influence future pricing but are not immediate factors.
Revenue Projections
| Year |
Estimated Prescription Volume |
Average Price per Tablet |
Projected Revenue (USD Millions) |
| 2023 |
150 million |
USD 1.00 |
USD 150 million |
| 2025 |
150 million |
USD 1.00 |
USD 150 million |
| 2030 |
140 million |
USD 1.00 |
USD 140 million |
Note: Volumes are assumed to remain steady, with minor fluctuations based on market competition and prescriber preferences.
Key Takeaways
- NDC 69238-1574 corresponds to a widely used sildenafil generic.
- The drug’s market in the U.S. is mature with stable, low pricing due to competition.
- Prices are unlikely to change significantly in the next 3–5 years; expected within USD 0.50–USD 2.00 per tablet.
- Industry trends favor continued generic competition, limiting price increases.
- Revenue projections remain stable at approximately USD 150 million annually in the short term, barring systemic market shifts.
FAQs
1. What factors could push prices higher?
Introduction of innovative formulations, supply shortages, or regulatory changes that extend patent exclusivity.
2. Could market consolidation affect prices?
Yes, if large firms dominate manufacturing, prices could increase marginally but unlikely in current competitive environment.
3. Are price differences significant across pharmacies?
Yes, variation exists due to negotiated discounts, loyalty programs, and geographic differences.
4. How does insurance coverage impact pricing?
Insurance often reduces out-of-pocket costs, leading to lower direct transaction prices for consumers.
5. What is the outlook for biosimilar or alternative therapies?
Potential future entries could impact market share and pricing, but none are imminent within current regulatory timelines.
References
[1] IQVIA. (2022). U.S. Prescription Market Data.
[2] FDA. (2022). Drug Approvals and Patent Information.
[3] Medscape. (2022). Erectile Dysfunction Market and Drug Pricing.
